Androgen Deprivation Therapy News and Research

RSS

SWOG researchers to present practice-changing research at virtual ASCO 2021

"SWOG always brings an impressive portfolio of work to the ASCO annual meeting," said SWOG Chair Charles D. Blanke, MD, "and this year I'm particularly excited about the research our investigators are presenting because it includes results that are likely to be practice-changing."

1 Jun 2021

City of Hope initiates Phase 2 clinical trial to investigate if mushroom tablets could slow prostate cancer

City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, is now recruiting patients for a Phase 2 clinical trial to investigate whether pills containing white button mushroom extract could regulate the immune system, affecting prostate-specific antigen (PSA) levels to either remain stable or decline.

29 Apr 2021

Male bladder cancer vulnerability could be exploited to design new therapeutic strategies

A protein variant common in malignant bladder tumor cells may serve as a new avenue for treating bladder cancer.

29 Apr 2021

Hormonal therapies for breast and prostate cancers increase the risk of heart attack, stroke

The hormonal therapies used to treat many breast and prostate cancers raise the risk of a heart attack and stroke, and patients should be monitored regularly and receive treatment to reduce risk and detect problems as they occur.

26 Apr 2021

Research explores sex differences in placental defenses against SARS-CoV-2 infection

A plethora of earlier studies has reported on the differences between the sexes in susceptibility to the currently circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as its severity. A new preprint research paper posted to the bioRxiv* server extends this to the placenta in pregnancy.

6 Apr 2021

Anti-androgen drugs may help disarm coronavirus spike protein, stop progression of COVID-19

Hormone drugs that reduce androgen levels may help disarm the coronavirus spike protein used to infect cells and stop the progression of severe COVID-19 disease, suggests a new preclinical study from researchers in the Abramson Cancer Center at the University of Pennsylvania and published online in Cell Press's iScience.

22 Mar 2021

Inflammation marker linked to increased fatigue in prostate cancer patients treated with ADT

Prostate cancer is one of the most common cancers among men in the U.S. For many patients, hormone therapy is a treatment option.

4 Jan 2021

FDA approves first oral drug for treating adult patients with advanced prostate cancer

Today, the U.S. Food and Drug Administration approved Orgovyx (relugolix) for the treatment of adult patients with advanced prostate cancer.

18 Dec 2020

Researchers report outcomes of salvage low dose RT brachytherapy after EBRT for prostate cancer

Researchers involved in the phase II NRG Oncology RTOG 0526 trial studying low dose rate (LDR) prostate brachytherapy (BT) following local recurrence (LR) after external beam radiotherapy (EBRT) for patients with low-to-intermediate risk prostate cancer reported late Grade 3 gastrointestinal and genitourinary adverse events (AEs) occurring in 14% of trial participants.

28 Oct 2020

Androgen deprivation strategies could help mitigate SARS-CoV-2 infection

Since the beginning of the COVID-19 pandemic, researchers have noted that women are generally less severely affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This has led to the exploration into estrogen and androgens' role in the hyperinflammatory clinical phenotypes of COVID-19. A recent study published on the preprint server bioRxiv shows that drugs targeting androgens and TMPRSS2 inhibitors may potentially combat the pandemic.

20 Oct 2020

Enzalutamide has added benefit for men with castration-resistant prostate cancer at high risk of metastasis

In 2018 and 2019, the German Institute for Quality and Efficiency in Health Care already investigated whether the drug enzalutamide has an advantage in comparison with the appropriate comparator therapy, i.e. in comparison with watchful waiting while maintaining ongoing conventional androgen deprivation therapy (ADT), for adult men with high-risk non-metastatic castration-resistant prostate cancer.

19 Aug 2020

Radiation therapy delay for prostate cancer patients offers room for flexibility during the pandemic

For cancer patients receiving radiation treatment during a surge in COVID-19 cases, adhering to the stay-at-home orders of quarantine is not always an option.

13 Aug 2020

Darolutamide shows indication of considerable added benefit in prostate cancer

Up to now, adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) at high risk of developing metastatic disease usually continued their conventional androgen deprivation therapy (ADT) while the cancer was observed for the occurrence of metastases (so-called watchful waiting).

3 Aug 2020

Study shows moderate exercise reduces side effects of prostate cancer treatment

New research published this weekinExperimental Physiologyfound that in prostate cancer survivors,a moderate bout of exercise kept the cell count of certain type of immune cells at a normal level, suggesting the exercise is safe for prostate cancer survivors.

29 Jul 2020

Clinical trial shows anti-tumor responses in metastatic castration-resistant prostate cancer patients

The preliminary results of a Phase I clinical trial conducted by researchers at the Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC protein degrader, demonstrates clinical evidence of anti-tumor responses in patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed prior therapy.

29 May 2020

Multi-institutional clinical trial sheds new light on non-responsive tumors

Over the last decade, enzalutamide and similar drugs have led to significant tumor control and increased survival time for men who have metastatic prostate cancer that continues to grow despite treatments to reduce male hormone levels.

19 May 2020

Study provides insight into regenerative potential of prostate gland

The standard treatment for men with advanced prostate cancer is androgen-deprivation therapy. Androgens are hormones that fuel prostate cell growth; removing them with either drugs or surgery causes the prostate gland to shrink by 90%.

30 Apr 2020

Prostate cancer mortality rates predicted to fall in the EU but rise in Poland

Death rates from prostate cancer are predicted to fall in 2020 in the EU, largely due to better diagnosis and treatment, according to new research published in the leading cancer journal Annals of Oncology today (Monday).

20 Apr 2020

Death rates from prostate cancer predicted to decline overall in EU

Death rates from prostate cancer are predicted to fall in 2020 in the EU, largely due to better diagnosis and treatment.

17 Apr 2020

Mathematical model can predict patient outcomes to adaptive prostate cancer therapy

Prostate cancer is the most common malignancy among men in the United States. It is also the second most common cause of cancer-related deaths. Despite improved treatments for prostate cancer, many patients with advanced disease eventually develop drug resistance.

9 Apr 2020